deferasirox has been researched along with Acute Myelogenous Leukemia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Andreani, G; Bracco, E; Calabrese, C; Cilloni, D; De Gobbi, M; Fava, C; Frassoni, F; Maglione, A; Napoli, F; Panuzzo, C; Pergolizzi, B; Petiti, J; Pironi, L; Ravera, S; Saglio, G; Scaravaglio, P; Shahzad Ali, MS; Stanga, S | 1 |
| Cho, BS; Cho, SG; Eom, KS; Hahn, AR; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lee, TH; Min, CK; Min, WS; Park, SS; Yoon, JH | 1 |
| Campos, VF; Cruz, LR; Danilow, MZ; dos Santos, VM; Paixão, GT; Ribeiro, EF | 1 |
| Butler, J; Curley, C; Durrant, S; Kennedy, GA; Morris, KL; Subramonpillai, E | 1 |
| Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E | 1 |
| Alkhaeir, S; Callens, C; Damaj, G; Dussiot, M; Gorin, NC; Hermine, O; Isnard, F; Marolleau, JP; Monteiro, RC; Moura, IC; Paubelle, E; Rubio, MT; Suarez, F; Zylbersztejn, F | 1 |
| Tohyama, K | 1 |
| Merkel, DG; Nagler, A | 1 |
| Bae, SH; Chung, JS; Hyun, MS; Joo, YD; Kim, H; Kim, HG; Kim, IH; Kim, SH; Kim, YS; Kwon, KY; Lee, GW; Lee, HS; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, KT; Ryoo, HM; Sohn, SK | 1 |
| Bahcebasi, S; Cetin, M; Deniz, K; Eser, B; Kaynar, L; Kurnaz, F; Ozturk, A; Pala, C; Sivgin, S; Unal, A; Uzer, E | 1 |
| Kato, J; Matsuki, E; Matsumoto, K; Nakaya, A; Okamoto, S; Yamane, A | 1 |
2 review(s) available for deferasirox and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Topics: Administration, Oral; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyridones; Triazoles | 2014 |
2 trial(s) available for deferasirox and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia.
Topics: Adult; Aged; Benzoates; Consolidation Chemotherapy; Deferasirox; Early Termination of Clinical Trials; Female; Ferritins; Humans; Iatrogenic Disease; Induction Chemotherapy; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2013 |
Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Deferasirox; Erythrocyte Transfusion; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Triazoles | 2015 |
7 other study(ies) available for deferasirox and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
Topics: Cell Line, Tumor; Deferasirox; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Mitochondria; Protein Stability; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Tumor Suppressor Protein p53 | 2020 |
Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Deferasirox; Female; Ferritins; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2019 |
Mucormycosis in a patient with acute myeloid leukemia successfully treated with liposomal amphotericin B associated with deferasirox and hyperbaric oxygen.
Topics: Adult; Amphotericin B; Antifungal Agents; Benzoates; Bone Marrow; Deferasirox; Drug Therapy, Combination; Female; Humans; Hyperbaric Oxygenation; Immunophenotyping; Karyotyping; Leukemia, Myeloid, Acute; Mucormycosis; Nucleophosmin; Treatment Outcome; Triazoles | 2013 |
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles | 2014 |
Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzoates; Case-Control Studies; Cell Differentiation; Deferasirox; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Cells; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Triazoles; Vitamin D | 2013 |
Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
Topics: Adolescent; Adult; Benzoates; Deferasirox; Female; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Kidney; Leukemia; Leukemia, Myeloid, Acute; Liver; Male; Middle Aged; Phlebotomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Triazoles; Young Adult | 2012 |
[Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes].
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2012 |